Access Pharmaceuticals, Tacora Corp. deal

The companies signed a letter of intent under which AXCS will acquire Tacora, a privately held developer of drug delivery technologies, for up to $14 million in common stock. AXCS's shares, which are traded on the Bulletin Board, have ranged between $2.25 and $2.50 over the past month, according to President and CEO Kerry Gray. AXCS has 31 million common shares outstanding prior to the deal. The purchase price is contingent upon achievement of technology milestones. ...